Navigation Links
AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
Date:8/4/2008

CONDENSED Consolidated Statements Of Cash Flows

(Unaudited)

(in thousands)

Six Months Ended

June 30,

2008 2007

Operating activities

Net loss $(564) $(334)

Adjustments to reconcile net loss to cash

provided by operating activities:

Depreciation and amortization 552 538

Provisions for (recoveries from) bad debts 110 (341)

Loss on disposal of fixed assets 6 -

Amortization of software development costs 1,060 979

Non-cash stock compensation expense 618 1,034

Changes in operating assets and liabilities:

Accounts receivable (1,607) (52)

Computer hardware held for resale,

prepaid expenses, and other 904 854

Accounts payable and accrued expenses (630) 922

Deferred revenue including unearned

discount 778 993

Unrecognized tax benefits 50 46

Cash provided by operating activities 1,277 4,639

Investing activities

Purchases of property and equipment (492) (264)

Purchase of software - (2,300)

Purchases of held-to-maturity securities (189,410) (44,592)

Maturities of held-to-maturity securities 175,642 44,174

Purchases of available-for-sale securities (5,597) (13,587)

Sales of availa
'/>"/>

SOURCE AMICAS, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Arcadia Radiology Medical Group Chooses AMICAS
2. AMICAS Announces Integrations at More Than 100 MEDITECH Facilities
3. AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008
4. AMICAS to Present at CIBC World Markets 18th Annual Healthcare Conference
5. eResearchTechnology Reports Second Quarter 2008 Results
6. SuperGen Reports 2008 Second Quarter Financial Results
7. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
8. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
9. CV Therapeutics Reports 2008 Second Quarter Financial Results
10. Gentiva Reports Strong Second Quarter led by Home Health Segment
11. United Therapeutics Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014  United Therapeutics Corporation (NASDAQ: ... (NYSE: MDT ) has submitted a ... Drug Administration (FDA) for the use of Medtronic,s ... (including a newly developed catheter) for use with ... intravenously to patients with pulmonary arterial hypertension.   ...
(Date:12/24/2014)... GMO corn cases filed across the ... in the process of being consolidated in a Kansas ... In Re: Syngenta AG MIR 162 Corn Litigation, MDL ... District of Kansas. , Management of the Syngenta GMO ... U.S. District Judge John W. Lungstrum.* , As a ...
(Date:12/24/2014)... The report provides basic ... definition, classification, application and industry overview. This ... and product cost structure. Production is separated ... also covers upstream raw materials, equipment, downstream ... and proposals. In the end, the export ...
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... - In Wisconsin, there is a growing belief that ... the loss of local ownership inevitably harms the state's economy. ... Corp . by Illinois-based CDW Corp . has a ... to those closest to the deal. , ,The win-win view ...
... expiring patents, generic drugs, and increasing costs of ... are increasingly turning to innovative biotechnology companies to ... business opportunities. , ,At a recent meeting of ... , pharmaceutical company representatives from Astellas Pharma, ...
... second consecutive year, the City of Madison received ... municipalities in the country. , ,In its 2006 Digital ... national research and advisory institute on information technology and best ... the top user of technology in its 125,000-249,999 population category. ...
Cached Biology Technology:Anatomy of a deal: CDW and Berbee 2Anatomy of a deal: CDW and Berbee 3Anatomy of a deal: CDW and Berbee 4Big pharma seeks Wisconsin biotech partnerships 2
(Date:12/19/2014)... --  LaunchKey , the first decentralized mobile authentication and ... Things era, today announced the close of $3 million ... by Metamorphic Ventures with participation from ENIAC Ventures, Crosslink ... LaunchKey has raised $4 million to date, and will ... bring LaunchKey to market in 2015. LaunchKey ...
(Date:12/17/2014)... 15, 2014 The Defense Logistics Agency ... to detect and prevent counterfeit microcircuits from entering ... agency started performing an in-house microcircuit anti-counterfeit initiative ... authenticity of purchased microcircuits while increasing their reliability ... measures will be conducted at DLA,s Electronics Product ...
(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... Nautiloids are the sole surviving family of externally-shelled ... million years ago. However, in the intervening years ... and developed complex central nervous systems; which makes ... that led to the development of the complex ...
... Micro gyro . . . Airplanes, submarines ... arrays of inexpensive high-performance micro-mechanical gyroscopes for navigation and ... being developed by a team consisting of Panos Datskos, ... Laboratory is radically different than today,s gyroscopes, which are ...
... highly developed emotional sensibilities are better at making product ... of Consumer Research. "Consumers who understand their emotional ... health decisions and product choices," explain the authors, Blair ... of Kentucky). "A person can know a lot about ...
Cached Biology News:Story tips from the Department of Energy's Oak Ridge National Laboratory, June 2008 2Story tips from the Department of Energy's Oak Ridge National Laboratory, June 2008 3
...
... Peptide-Protein Conjugation, ... Bridges, Complex Peptides/Peptidomimetics, Special ... Phosphorylated/Biotinylated Structures, Peptide labeling AMC, ... -99%, fitting your needs, Chromogenic/Flurogenic ...
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to KLH (Keyhole Limpet Hemocyanin) lysine through amide bonds....
...
Biology Products: